sermorelin dosing: Frequently asked questions

Reduce the dose by 50 mcg and reassess after one week. Flushing results from peripheral vasodilation triggered by the GH pulse and typically resolves as the body adapts to consistent dosing. If flushing persists at the reduced dose, slow the injection speed to 30–45 seconds rather than a rapid bolus. This blunts the peak plasma concentration spike that drives the vasodilatory response. Persistent flushing beyond two weeks at any dose may indicate histamine sensitivity to the bacteriostatic water preservative (benzyl alcohol). Switching to sterile water for reconstitution eliminates this variable but requires discarding the vial after seven days instead of 30.

Administer the missed dose as soon as you remember if it's still evening and you haven't eaten within three hours. Sermorelin works by amplifying natural GH pulses, so missing one dose doesn't create a gap in coverage the way skipping a medication with steady-state pharmacokinetics would. If you remember the next morning, skip the missed dose entirely and resume your regular schedule that evening. Doubling up provides no benefit because the pituitary's secretory capacity per pulse is fixed. Consistency matters more than perfection: missing one dose per week has minimal impact on cumulative IGF-1 elevation over 12 weeks.

Verify timing and fasting compliance first. Administering sermorelin too close to meals or during the daytime refractory period produces minimal response regardless of dose. If protocol adherence is confirmed and IGF-1 remains at baseline, titrate to 400 mcg for another four weeks before retesting. Approximately 15–20% of individuals are low responders due to polymorphisms in GHRH receptor density or downstream hepatic IGF-1 synthesis pathways. If 500 mcg produces no measurable IGF-1 elevation after eight weeks, sermorelin may not be the appropriate GH secretagogue. Alternatives like ipamorelin or CJC-1295 work through different receptor pathways.

Missing a nightly sermorelin dose means you forfeit that evening's amplified GH pulse, but it doesn't disrupt the overall protocol. Do not double-dose the following night. This won't compensate for the missed pulse and may cause an exaggerated GH spike that triggers feedback inhibition. Resume your normal schedule the next evening. Sermorelin's short half-life means there's no cumulative plasma buildup, so skipping a dose doesn't create a deficit that compounds over time. Consistency matters more than perfection: five well-timed doses per week outperform erratic daily dosing.

Morning sermorelin administration works mechanistically but misses the largest natural GH pulse, which occurs 60–90 minutes after sleep onset. Injecting in the morning amplifies a smaller endogenous pulse, yielding lower peak GH levels than a bedtime dose would produce. Some protocols intentionally use morning dosing to support daytime anabolic processes (muscle protein synthesis, lipolysis) when combined with resistance training. If your primary goal is maximizing total GH output, bedtime dosing remains superior. If your goal is daytime metabolic support, morning administration paired with a second secretagogue (like ipamorelin) later in the day can create a staggered pulse pattern.

Administering sermorelin more than once daily provides no additional GH benefit and may reduce overall effectiveness. Each injection triggers a pituitary GH pulse that lasts 2–4 hours. Administering a second dose during that window hits a refractory period where the pituitary is already releasing stored GH. The second injection produces minimal incremental response. Worse, frequent dosing can desensitize GHRH receptors through tonic stimulation, blunting future pulses. If your goal is sustained GH elevation throughout the day, a single nightly sermorelin dose combined with daytime ipamorelin (a ghrelin receptor agonist with complementary kinetics) produces better synergy than multiple sermorelin injections.

Recalculate your actual concentration immediately using the formula: total peptide (mcg) ÷ water added (mL) = concentration (mcg/mL). If you added 4mL instead of 2mL to a 5mg vial, your concentration is 1,250 mcg/mL instead of 2,500 mcg/mL. Every 0.1mL injection delivered 125 mcg instead of the intended 250 mcg. You've been underdosing by 50%. The vial isn't ruined, but you need to double your injection volume going forward to reach prescribed dose, which means you'll exhaust the vial in half the expected doses. Do not attempt to 'make up' missed doses by doubling the next injection. Maintain consistent daily dosing and adjust volume per the corrected calculation.

Potency declines approximately 5–10% beyond the 28-day mark when refrigerated properly. If you're at day 35 and have five doses remaining, expect each injection to deliver roughly 90% of labelled dose. Not therapeutically useless but suboptimal. The decision to continue or discard depends on protocol sensitivity: if the research endpoint requires precise dosing (growth hormone response studies, metabolic tracking), discard and start a fresh vial. If the protocol tolerates minor variance (general wellness research, non-critical endpoints), you can use the remaining doses with the understanding that they're underpotent. Never extend past 42 days. Degradation accelerates beyond six weeks and potency drops below 80%.

Request smaller vial sizes from your supplier. Real Peptides offers 2mg, 5mg, and 10mg sermorelin vials specifically to match protocol duration with peptide stability windows. If your research requires 12 doses total (three weeks at four injections per week), a 2mg vial reconstituted to yield exactly 12 doses ensures zero waste and maximum potency per injection. Oversizing the vial 'for convenience' results in discarding half the peptide or using degraded doses at protocol end. Neither outcome serves research integrity.